Disease-modifying therapies for relapsing/active secondary progressive multiple sclerosis – a review of population-specific evidence from randomized clinical trialsAntonios Bayas, Sven G. Meuth, Monika Christ et al.|Therapeutic Advances in Neurological Disorders|2023Cited by 25
Different Treatment Outcomes of Multiple Sclerosis Patients Receiving Ocrelizumab or OfatumumabSven G. Meuth, Steffen Pfeuffer, S. Wolff et al.|Annals of Neurology|2024Cited by 19
Effect of Previous Disease-Modifying Therapy on Treatment Effectiveness for Patients Treated With OcrelizumabSteffen Pfeuffer, Sven G. Meuth, Leoni Rolfes et al.|Neurology Neuroimmunology & Neuroinflammation|2023Cited by 10